A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus.
Menon M, Blair PA, Isenberg DA, Mauri C. · 2016
Read A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. by Menon M, Blair PA, Isenberg DA, Mauri C. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4803914.txt.
Introduction
Madhvi Menon, Paul A. Blair, David A. Isenberg, and Claudia Mauri uncover a broken peace treaty between two immune cell types in Immunity in 2016. In healthy people, sentinel cells called pDCs coach young B cells into regulatory B cells, which calm immune attack by releasing IL-10. The regulatory cells then rein in the sentinels' own alarm output, closing a feedback loop.
In lupus, the loop fails. Patient sentinel cells pushed B cells toward antibody factories instead of regulators, so the calming cells never formed in proper number. Flooding healthy B cells with the alarm signal copied the fault, and the signal switches inside the cells showed a skewed pattern. In patients who answered to a B-cell drug, both the cell talk and the switch pattern returned to normal.
Catalog record
| CREATOR | Menon M, Blair PA, Isenberg DA, Mauri C. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus By Madhvi Menon, Paul A. Blair, David A. Isenberg, Claudia Mauri Published in: Immunity DOI: 10.1016/j.immuni.2016.02.012 ABSTRACT Summary Signals controlling the generation of regulatory B (Breg) cells remain ill-defined. Here we report an “auto”-regulatory feedback mechanism between plasmacytoid dendritic cells (pDCs) and Breg cells. In healthy individuals, pDCs drive the differentiation of CD19+CD24hiCD38hi (immature) B cells into IL-10-producing CD24+CD38hi Breg cells and plasmablasts, via the release of IFN-α and CD40 engagement. CD24+CD38hi Breg cells conversely restrained IFN-α production by pDCs via IL-10 release. In systemic lupus erythematosus (SLE), this cross-talk was compromised; pDCs promoted plasmablast differentiation but failed to induce Breg cells. This defect was recapitulated in healthy B cells upon exposure to a high concentration of IFN-α. Defective pDC-mediated expansion of CD24+CD38hi Breg cell numbers in SLE was associated with altered STAT1 and STAT3 activation. Both altered pDC-CD24+CD38hi Breg cell interactions and STAT1-STAT3 activation were normalized in SLE patients responding to rituximab. We propose that alteration in pDC-CD24+CD38hi Breg cell interaction contributes to the pathogenesis of SLE. INTRODUCTION Regulatory B (Breg) cells exhibit immunosuppressive functions via the release of IL-10, transforming growth factor (TGF)-β, and IL-35 and by induction of other regulatory cells (Mauri and Bosma, 2012, Mauri and Nistala, 2014). In healthy individuals, immature B cells have been shown to regulate T cell responses via the release of IL-10, suppressing T helper 1 (Th1) and Th17 cell differentiation, and by converting effector CD4+ T cells into FoxP3+CD4+ regulatory T (Treg) cells (Blair et al., 2010, Flores-Borja et al., 2013). In several autoimmune diseases, including SLE and rheumatoid arthritis (RA), Breg cells are functionally and numerically impaired (Blair et al., 2010, Flores-Borja et al., 2013). Signals required for the differentiation of human Breg cells remain poorly understood. CD123+BDCA-2+ plasmacytoid dendritic cells (pDCs) are important drivers of innate and adaptive immune responses (McKenna et al., 2005, Reizis et al., 2011). pDCs rapidly produce large amounts of interferon alpha (IFN-α) upon toll-like receptor (TLR) activation during viral infections or in response to neutrophil extracellular traps (NETs) (Gilliet et al., 2008, Hoffmann et al., 2015, Garcia-Romo et al., 2011, Swiecki and Colonna, 2015). In SLE, neutrophils die upon exposure to SLE-derived anti-ribonucleoprotein antibodies and release NETs containing endogenous DNA as well as neutrophil proteins that enter pDC endocytic compartments and activate them to produce high amounts of IFN-α (Garcia-Romo et al., 2011, Lande et al., 2011). IFN-α stimulates multiple cell types, including natural killer (NK) cells, monocytes, myeloid DCs, and T cells, to release a variety of pro-inflammatory cytokines (McKenna et al., 2005). IFN-α produced by pDCs is pivotal in driving the maturation of B cells into plasmablasts (Jego et al., 2003, Poeck et al., 2004). pDCs can induce the differentiation of IL-10-producing T cells and FoxP3+ Treg cells to counterbalance inflammatory responses and to prevent excess inflammation (Ito et al., 2007, Moseman et al., 2004, Swiecki and Colonna, 2015). IFN-α-induced gene signature, together with defects in B cell function, is considered the hallmark of SLE (Bennett et al., 2003, Obermoser and Pascual, 2010). In SLE, chronic activation of pDCs and other cells results in enhanced IFN-α and IFN-α/β receptor (IFN-α/βR) signaling on target cells (Rönnblom and Eloranta, 2013). Higher amounts of IFN-α production in SLE are associated with an accumulation of plasma cells, increased autoantibody, defective apoptotic cell clearance, and promotion of T-cell-dependent inflammation (Li et al., 2015, Pascual et al., 2006). In lupus-prone transgenic mice, transient depletion of pDCs prior to disease initiation reduces autoantibody, type I IFN signature, and kidney pathology compared to undepleted mice (Rowland et al., 2014). Similarly, IFN-α/βR blockade inhibits autoantibody production and protects young lupus-prone BXSB or MRL-Faslpr mice from disease, highlighting a role for pDCs in the disease initiation (Baccala et al., 2012). Furthermore, IRF8-deficient NZB mice, which lack pDCs, display a profound reduction in anti-nuclear, anti-chromatin, and anti-erythrocyte autoantibodies, as well as a significant reduction in kidney disease (Baccala et al., 2013). In addition, mice lacking E2-2, a transcription factor that regulates pDC development, display impaired pDC function, a dramatic reduction in anti-DNA autoantibody production, and glomerulonephritis as well as ameliorated disease (Sisirak et al., 2014). Several studies have linked type I IFNs with an increase in IL-10 production by B cells (Matsumoto et al., 2014, Schubert et al., 2015). However, the role of pDCs and/or type I IFNs in determining whether a B cell becomes a Breg cell or an antibody-producing plasmablast remains unknown. Our data demonstrate that pDCs can generate plasmablasts that co-express IL-10, IL-6, and TNF-α and release antibody, as well as CD24+CD38hi Breg cells. CD24+CD38hi Breg cells provided negative feedback and restrained excessive IFN-α production by pDCs via IL-10 release. In SLE, pDCs failed to induce the differentiation of CD24+CD38hi Breg cells but promoted antibody production. Similarly, in vitro stimulation of healthy B cells with high concentrations of IFN-α failed to expand CD24+CD38hi Breg cells but promoted plasmablast differentiation. In comparison to healthy controls, immature B cells from SLE patients displayed altered STAT1 and STAT3 activation and expressed higher amounts of TNF-α and IL-6 than IL-10. Of note, newly repopulated immature B cells in SLE patients responding to rituximab showed normalized expression of STAT1 and STAT3 and could differentiate into CD24+CD38hi Breg cells. RESULTS pDCs Expand CD24+CD38hi Breg Cells in Healthy Individuals To test whether pDCs could generate Breg cells, as well as plasma cells as previously reported (Jego et al., 2003), we co-cultured negatively isolated healthy B cells with autologous pDCs for 3 days with CpGC, a TLR9 agonist that stimulates both pDCs and B cells (Hartmann et al., 2003). Figures S1A and S1B show the purity of isolated B cells and pDCs. In addition to inducing the differentiation of CD24−CD38hi B cells (plasmablasts), stimulation with pDCs and CpGC induced an expansion of CD24+CD38hi B cells (Figure 1A) (comprising CD24hiCD38hi and CD24intCD38hi B cells as shown in Figure S1C). Of note, both CD24hiCD38hi and CD24intCD38hi B cells were IgMhi, IgDhi, and CD27−, characteristic of B cells at an immature stage of development (Figures S1D). Further phenotypical analysis confirmed that the pDC-expanded plasmablasts were CD27+, IgD−, and IgMlo, whereas pDC-expanded CD24+CD38hi B cells were also CD27−, IgDhi, and IgMhi (Figure 1B). In addition to expanding B cells with an immature phenotype that has previously been associated with Breg cells (Blair et al., 2010), pDCs induced a 4-fold enrichment of IL-10-producing B cells compared to B cells stimulated with CpGC alone (Figure 1C). An expansion of IL-10-producing B cell numbers was observed even at low ratios (up to 1:50 pDCs:B cells) (Figure S1E). Analysis of the co-culture supernatants confirmed significantly increased amounts of IL-10 (Figure 1D). IL-10+ B cells generated by pDCs expressed higher Ki67 than IL-10+ B cells generated on stimulation with CpGC alone (Figure S1F). The majority of IL-10+ B cells induced by pDCs were CD24+CD38hi B cells, with a smaller percentage residing within the plasmablast population, also previously ascribed with regulatory capacity (Figure 1E; Matsumoto et al., 2014). The majority of IL-10+ B cells were CD27−CD38hi B cells, with a smaller percentage found within the CD27+CD38hi population (Figure S1G). CpGC-stimulated pDCs displayed an enhanced ability to expand IL-10+ B cells